ACP 2026 Recap: Mammography, AI Scribes, Obesity Medications, and Breast Cancer Screening Guidelines Debate

The American College of Physicians released new guidance on mammography screening for breast cancer during its Internal Medicine Meeting 2026 in San Francisco, recommending biennial screening for average-risk women aged 50 to 74.

The guidance, published concurrently in Annals of Internal Medicine, was presented by Carolyn Crandall, M.D., Professor of Medicine at the David Geffen School of Medicine at UCLA and Chair of ACP’s Clinical Guidelines Committee, who provided context and rationale for the recommendations during a live scientific plenary session.

Dr. Crandall explained that women at average risk between the ages of 50 and 74 should undergo biennial mammography screening for breast cancer, a recommendation intended to balance the benefits of early detection with the potential harms of over-screening, including false positives and unnecessary procedures.

The ACP’s position reflects an evidence-based approach aimed at reducing screening frequency for certain age groups while maintaining focus on populations most likely to benefit from routine mammography.

In addition to the mammography guidance, the plenary session featured two other breaking research articles presented by their authors: one on the use of artificial intelligence for medical documentation and another on the effect of weight loss medications on body composition.

Annals of Internal Medicine Editor-in-Chief Christine Laine, M.D., MPH, and ACP Senior Vice President introduced the authors and facilitated discussion on each topic, emphasizing the journal’s role in disseminating timely, peer-reviewed research directly at the point of clinical practice.

The articles were published in Annals of Internal Medicine concurrently with their live presentation at the meeting, ensuring immediate access to the latest evidence for internal medicine practitioners.

Presenters highlighted that the AI in medicine discussion focused on ambient scribes and automated documentation tools designed to reduce clinician burnout by streamlining electronic health record entry during patient encounters.

Regarding obesity medications, researchers examined how glucagon-like peptide-1 (GLP-1) receptor agonists and related therapies influence not only weight reduction but also changes in fat distribution, lean muscle mass, and overall body composition, with implications for long-term metabolic health.

The session underscored ACP’s commitment to translating scientific findings into practical guidance for primary care, particularly in areas where evolving evidence necessitates periodic reassessment of established practices.

By aligning its recommendations with current data on screening efficacy, technological innovation in healthcare delivery, and the metabolic impacts of pharmacological obesity treatment, the ACP aims to support physicians in delivering individualized, evidence-based care.

The Internal Medicine Meeting 2026 continues to serve as a key forum for the dissemination of breaking medical research, with Annals of Internal Medicine playing a central role in connecting scientific discovery with clinical application.